Anvisa bans medication lots to treat cancer
Suspicion is that they are counterfeit products
By Fabiano Blageski
10/19/2026 · 07:40 PMUpdated 20:451 min read
Advertisement
The National Surveillance Agency (Anvisa) determined the seizure of batches Z005197 and Z012354 of the drug Keytruda (pembrolizumab) 100 mg/4 mL, indicated for the treatment of various types of cancer.
The decision was published on Monday (19) in the Official Journal of the Union.
In a note, Anvisa reported that the company itself holding the product registration, Merck Sharp & amp; Dohme Farmacêutica Ltda., identified in the market units of the lots with characteristics diverging from those contained in the original medicine.
The suspicion is that they are counterfeit products.
https://www.youtube.com/watch?v=PgW00_-a8RM&t=2125s
Want to see BnT more often on Google?
Author
Fabiano Blageski
Radialista em Ponta Grossa, atuou em rádios, TV e sites, com experiência no microfone e nos bastidores. Apaixonado por comunicação, entretenimento e notícias, também é promoter de eventos, assessor de imprensa, destacando-se pela versatilidade e busca constante por aprendizado.
See all stories →Advertisement
